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Background: In kidney transplantation, the use of Anti-Thymocyte Globulins (ATG) as induction therapy has been
described as a possible treatment for reducing the prevalence of Delayed Graft Function (DGF). ATG possesses
pharmaceutical proprieties that could help control the lesions caused by ischemia reperfusion injury. However,
other studies have questioned this potential protective effect. We hypothesized that the benefits related to ATG for
reducing DGF prevalence may be higher and more consistently recognized if only patients with high DGF risk are
considered. We recently proposed a scoring system entitled DGFS (Delayed Graft Function Score) for such
stratification of kidney transplant recipients according to their risk of DGF. Using the DGFS calculation, we aim to
determine whether a short course of ATG can decrease the incidence of DGF in comparison with Basiliximab in
kidney transplant recipients with low immunological risk but high DGF risk.
Methods: We conduct a phase IV, open label, randomized, multicentric and prospective study, to compare ATG in
parallel with a control group treated by Basiliximab. The 1:1 randomized allocation of patients between groups is
stratified on the clinical center, and on the hypothermic machine-perfusion device. We aimed to include a total
of 384 patients to achieve a statistical power at 0.80. The study was initiated at the Nantes University hospital in
July 2014, with data collection continuing until April 2018, and publication of the results proposed for 2019.
Discussion: The main expected benefits of this study are i) the reduction of unjustified ATG over-prescriptions
associated with serious adverse events, ii) the reduction of chance losses related to ATG under-prescription,
iii) the decrease in the incidence of DGF which was described as a risk factor of graft failure and patient death,
and iv) the reduction in hospitalization duration and number of post transplantation dialysis sessions, both being
associated with reduced medical costs. In conclusion, the current study is innovative by proposing a more efficient
and personalized induction therapy.
Trial registration: The study was registered in the Clinical Trials Registry (#NCT02056938, February 5, 2014), and in
the European Clinical Trials Database (EudraCT #2014-000332-42, January 30, 2014).
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The current 10-year patient and graft survival of first
kidney transplantation varies from 25 % to 40 % de-
pending on inclusion criteria and countries. Therefore,
much still has to be done to improve long-term out-
comes for kidney transplant recipients. As part of this
objective, delayed graft function (DGF) is well known
among the main risk factors of poor long-term out-
come, increased hospitalization duration and acute re-
jection [1, 2]. DGF is the major clinical manifestation
of renal injuries that are linked to ischemia reperfusion
injury. Until now, this has been unavoidable in kidney
transplantation and occurs after cold and warm preser-
vation of the kidney. Preventing DGF by focusing primar-
ily on donor management, organ procurement, infusion
and preservation supplies, and drug monitoring, is thus
probably the most beneficial strategy for prolonged
long-term graft and patient survival. Thus, the predic-
tion of DGF is of primary importance in kidney trans-
plantation for adapting as far as possible the medical
management of high-risk transplantations.
However, although the risk factors for DGF have been
well-described in the literature for a number of years, it
is difficult to predict this complication in practice at an
individual level. Several scoring systems have been pro-
posed within the last few years [3, 4], but these are not
used routinely for medical decision making because of
the important number of included parameters or the
absence of validation. Therefore, we recently proposed
an alternative scoring system entitled the delayed graft
function score (DGFS) [5]. The DGFS is composed of
only five variables: the cold ischemia time, the donor
age, the last donor serum creatinine level, the recipient
body mass index, and the induction therapy used. The
DGFS is associated with a good predictive capacity, with
area under the receiver operator characteristic (ROC)
curve at 0.73 (95 % CI from 0.68 to 0.77). By using the
learning sample, we calculated a DGFS threshold value
at 0.4 to obtain a positive predictive value of 40 %, an ac-
ceptable percentage to consider recipients with a high
risk of DGF (the overall percentage of DGF was 25.1 %).
By using the validation sample, this decision rule corre-
sponds to sensitivity of 47.5 % (95 % CI from 40.3 to
55.0), a specificity of 83.5 % (95 % CI from 79.5 to 86.9),
a positive predictive value of 57.7 % (95 % CI from 48.5
to 64.5), and a negative predictive value of 77.9 % (95 %
CI from 73.7 to 81.6).
The use of anti-thymocyte globulins (ATG, Thymo-
globuline®, Sanofi) as induction therapy has already
been described as a possible treatment for reducing
the prevalence of DGF [6–8]. ATG possesses pharma-
ceutical proprieties that could help to control or pre-
vent the lesions caused by ischemia reperfusion injury.
However, other studies have questioned this possibleprotective effect [9–12]. Therefore, despite this well-
established depleting treatment as an induction therapy
in patients with high immunological risk [13], there is
no consensus on whether ATG is better than basilixi-
mab (anti IL2-R, Simulect®, Novartis) to prevent DGF
for patients with a low immunological risk. We hypothe-
sized that the benefit related to ATG for reducing DGF
prevalence may be higher than expected if only proposed
to patients with high DGF risk.
The main objective of the PREDICT-DGF study out-
lined here is to determine whether a short course of
ATG is more efficient than basiliximab in decreasing the
incidence of DGF in kidney transplant recipients with
low immunological risk, but high DGF risk assessed
by the DGFS calculation. We also aim to evaluate the
risk/benefit ratio related to induction therapy by ATG
in patients with low immunological risk, i.e., the con-
sequences of a possible reduction in DGF incidence,




We are conducting a phase IV, open label, randomized,
multicenter prospective study, to compare ATG in paral-
lel with a control group treated by basiliximab. The 1:1
randomized allocation of patients between groups is
stratified on the clinical center, and on the hypothermic
machine-perfusion device. The participation of each
patient is scheduled for 3 months. The study design is
outlined in Fig. 1.
Ethical approval and registration
All procedures will be explained to patients and the
informed consent form will be reviewed and signed.
The study was registered in the Clinical Trials Registry
(#NCT02056938), and in the European Clinical Trials
Database (EudraCT #2014-000332-42). It has received
approval from the ethical research committee (Tours,
France, Comité de Protection des Personnes – CPP, refer-
ence # 14/13-929) that is applicable for all French centers
involved in this study. The French national agency for
drugs safety also approved the study (Agence Nationale
pour la Sécurité du Médicament, ANSM # 140175A-11),
especially regarding the classification as a phase IV
study. ATG and basiliximab have both been approved
for marketing and the present protocol respects the
corresponding indications.
Study population
Recruitment is performed during pre-surgery hospi-
talization in one of the six participating centers (Lyon,
Montpellier, Nancy, Nantes, Nice, and Paris Necker).
Inclusion criteria are: 1) adults with end-stage renal
Fig. 1 Preventing delayed graft function by driving immunosuppressive
induction treatment (PREDICT-DGF) study: description of the study.
This randomized trial aims to compare anti-thymocyte globulin
(ATG)-treated patients in parallel with a control group treated by
basiliximab. The 1:1 randomized allocation of patients between
groups is stratified on the clinical center, and on the hypothermic
machine-perfusion device. The participation of each patient is
scheduled for 3 months
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occurrence of DGF, defined by the need for dialysis
within the first seven days post transplantation, is not
correctly evaluated for patients on peritoneal dialysis
or for patients who will receive pre-emptive trans-
plantation); 3) patients with kidneys transplanted from
deceased donors with heartbeat; 4) patients with writ-
ten informed consent; 5) patients affiliated with the
French social security system; 6) patients considered at
low immunologic risk (i.e., first kidney transplant re-
cipients with no anti-HLA immunization prior to trans-
plantation and sera negative for anti HLA immunization,
regardless of the technique used for this evaluation);
7) patients considered at high-risk of DGF (i.e., DGFS
higher than 0.4), and 8) patients without medical
contraindication to ATG (i.e., leukopenia lower than
3,000/mm3, thrombopenia lower than 100,000/mm3,
previous history of cancer (except basal cell skin can-
cers), current history of hepatitis C virus (HCV)/hepa-
titis C virus (HBV)/HIV infection, or Epstein-Barr virus
(EBV)-matching donor positive and recipient negative).For ethical considerations, pregnant or lactating women
and patients under guardianship are not included.
Calculation of delayed graft function score
The DGFS calculation is facilitated by an application avail-
able on smartphones, tablets or computers at www.
divat.fr/en/online-calculators. The results are exportable
as a simple file in portable document format (PDF).
Studied treatment (ATG)
Thymoglobuline® is used in this study. It is a rabbit
anti-human thymocyte immunoglobulin. The first infu-
sion begins prior to kidney reperfusion, to study the
potential effects on ischemia reperfusion injury mecha-
nisms [14–16]. In fever or respiratory syndrome related
to possible cytokine release, paracetamol (1 g every 6 h)
is prescribed, and Polaramine® (2 mg orally) prescribed in
patients with associated cutaneous rash. The total dur-
ation of Thymoglobuline® administration is 4 days, in-
cluding the first day of the surgery, with a daily dose of
1.5 mg/kg [17]. The monitoring of blood T cell deple-
tion provides information for the adaptation of the
Thymoglobuline® daily dose. The aim is to maintain
peripheral blood lymphocytes below 200/mm3 and CD3
counts below 20/mm3. Thymoglobuline® dosing is halved
if the white blood cell (WBC) counts falls below 2,000 −
3,000/mm3, or if the platelets fall in between 50,000 and
75,000/mm3. Thymoglobuline® is prematurely withdrawn
if the WBC falls below 2,000/mm3 or the platelets fall
below 50,000/mm3.
Control treatment (basiliximab)
The control treatment is Simulect®, which is a recombin-
ant murine/human chimeric monoclonal antibody di-
rected against the interleukin-2 receptor α-chain (CD25
antigen). Two infusions of Simulect® are performed with
a dose of 20 mg, the first immediately after surgery and
the second 3 days afterwards.
Other treatments
In parallel with Thymoglobuline® or Simulect®, the ther-
apy includes one intravenous bolus of corticosteroids
(methylprednisolone 500 mg). All patients receive the
same immunosuppressive maintenance therapy with
1) Tacrolimus (Prograf®) regardless of the delayed admin-
istration post-surgery which respects normal practice at
each center, and 2) mycophenolate mofetil (Cellcept®,
with a daily dose of 2 g) and prednisolone (with a dose of
1 mg/kg orally tapered at 10 mg every 5 days to a dose
of 5 mg until the surveillance biopsy at 3 months). Fi-
nally, concomitant prophylaxis by Trimethoprim/Sulfa-
methoxazole and Valgancyclovir will be used to prevent
pneumocystis and cytomegalovirus (CMV) infection.
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The primary endpoint will be the occurrence of a DGF
defined as the need for dialysis within the first seven
days post transplantation. This definition of DGF is
the most commonly recognized and published. Never-
theless, this definition is insufficient since the decision
to dialyze may not only depend on the insufficiency of
the post-transplantation renal function but also on
hyperhydration or hyperkaliemia for instance. The def-
inition of the DGF will thus consider, 1) the number
of days after transplantation to reach an estimated glom-
erular filtration rate (eGFR) above 10 mL/min, calculated
using the modification of the diet in renal disease
(MDRD) formula [18], 2) the evolution of the MDRD
eGFR until hospital discharge, and 3) the number of
dialyses performed after the transplantation without
taking into account dialysis exclusively prescribed for
hyperhydration or hyperkaliemia.
Secondary outcome measures
The following endpoints will also be considered: 1) the
occurrence of histologically proven acute rejection epi-
sodes within the 3 months following the transplantation
and subclinical acute rejection episodes on the 3-month
surveillance biopsies (BANFF 2011 classification); 2) the
percentage of renal fibrosis on the 3-month surveillance
biopsies using the computerized quantification described
by Meas-Yedid et al. [19]; 3) the time between trans-
plantation surgery and hospital discharge; 4) the evolu-
tion of the Tacrolimus trough level; 5) the hematologic
monitoring within the first three months after surgery
including WBC blood cell count, CD3 subpopulation
analysis, and CD4, CD8, CD19, natural killer (NK) cell,
and platelet counts, and 6) the occurrence of infections
within the study follow-up, especially CMV and BK vi-
ruses assessed at three months by RT-PCR, as either
primary or secondary infections.
Follow-up time
Follow-up at 3 months is required for the previous
endpoints for full completion of the study. Nevertheless,
patients will be followed for some years after the end of
the trial for incidence of cancer, post-transplant lym-
phoproliferative disorders, infections, graft and patient
survival. This will be possible because these patients will
be part of the prospective DIVAT cohort (www.divat.fr).
Sample size
Based on the results of the randomized trial pub-
lished by Noel et al. [13] and according to our previ-
ous observational study [5], we can expect 40 % DGF
in patients treated with basiliximab versus 28 % in
patients with ATG (odds ratio (OR) = 1.7). To respect
a type I error at 0.05 and a power at 0.80 (one-tailedtest), 192 patients will have to be included in each
group. We therefore aim to include a total of 384 pa-
tients. We chose one-tailed testing because no paper
has described a higher incidence of DGF for ATG-
treated patients compared to other non-depleting induc-
tion therapies. The literature heterogeneity consists in
the statistical significance of the ATG effect for prevent-
ing the DGF occurrence. Even if the two-tailed test takes
into account the possibility that the reference treatment
might be better [20], the one-tailed test seems the most
adapted in our situation for both ethical and cost-
efficiency considerations [21].
Data acquisition
Data collection will be performed by the investigators or
the clinical research assistants by using an electronic
case report form accessible from the web and developed
with Clinsight®. Data are anonymously extractable to
keep the identities of patients confidential.
Data analysis
Analysis will be performed by respecting the principle of
intention-to-treat analysis. No intermediate analysis will
be performed. Depending on the observed switches or
dropouts, per-protocol analysis may be secondarily per-
formed in order to evaluate the robustness of the find-
ings. According to the sample size and the random
assignment of treatments, both groups are expected to
be comparable. In order to validate this comparability,
a preliminary description of the two groups will be
performed according to the mean, standard deviation
and range for continuous variables, and according to
percentage and effective for categorical variables. For
binary endpoints, logistic regression with random inter-
cept and/or slope will be performed to estimate the treat-
ment effect, taking into account possible between-center
differences. The same methodology will be used to assess
the percentage of renal fibrosis and the time between
surgery and hospital discharge. However, these will use
linear models with random intercept and/or slopes.
P <0.05 will be considered statistically significant for all
tests. The statistical analyses will be performed using R
software [22].
Discussion
The study commenced at the Nantes University hospital
in July 2014, and the inclusion of the other centers will
be possible from September 2014, after the first phase of
development in Nantes. It is reasonable to schedule a
period of 42 months for patient recruitment, i.e., until
January 2018, as guided by the number of transplan-
tations usually performed among the six participating
centers. Given the follow-up of 3 months, the end of the
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lication of results for 2019.
The objective of our study is to reduce the preva-
lence of DGF to improve the long-term outcomes of
kidney transplant recipients. ATG is of potential inter-
est to such a reduction, but the possible benefits are
continually debated, probably due to the heterogeneity
of its indication between countries, between centers, and
even amongst physicians. Importantly, the main indica-
tion for this treatment is for patients with high immuno-
logical risk, i.e., patients having repeat transplantation
and/or HLA immunization prior to transplantation).
We hypothesized that the use of ATG in induction
could be more beneficial in patients who present a
low immunological risk but a high DGF risk. The use
of the DGFS, to objectively identify patients with high
DGF risk, is particularly important as it may allow
heterogeneity practices to be aligned.
The consequences of the PREDICT-DGF study may
be several-fold. One outcome may be to reduce exces-
sive ATG prescription, which is associated with serious
adverse events such as cytokine release syndrome, fever,
serum sickness, infectious disease or post-transplant lym-
phoproliferative disorders. Another outcome may be to
avoid ATG under-prescription and therefore to reduce
the incidence of DGF. We also expect a shorter hospital
stay, a reduction in the number of post transplantation
dialyses, both being associated with a reduction of med-
ical costs. Finally, this reduction may improve long-term
graft and patient survival.
In conclusion, the current study is innovative as it
will allow the effects of two types of induction therapy
in kidney transplant recipients with low immunological
risk to be evaluated, using for the first time a predict-
ive tool to assess the risk of DGF. We believe this will
result in a more efficient and personalized induction
therapy.Trial status
The trial is ongoing.Abbreviations
CMV: cytomegalovirus; DGF: delayed graft function; DGFS: delayed graft
function score; ATG: anti-thymocyte globulins; WBC: white blood cell;
MDRD: modification of the diet in renal disease; eGFR: estimated glomerular
filtration rate; PREDICT-DGF: preventing delayed graft function by driving
immunosuppressive induction treatment.Competing interests
This study was supported by a grant from the French Ministry of Health
(PHRC-13-0523, 2013) and financial support from Sanofi (the laboratory
providing the Thymoglobuline®). Nevertheless, the principal investigator of
the trial is free to publish all the results of this trial. The publication of this
protocol is an additional guarantee of this independence. No authors have
any non-financial competing interests.Authors’ contributions
MC, YF, and MG are responsible for study conceptualization. MG is the
principal investigator. CL, EM, GM, ML and EC are co-investigators in Paris
Necker, Lyon, Montpellier, Nancy and Nice. KN, EP and MM organize the trials
in practice. PD is in charge of the web application related to the DGFS. All
authors read and approved the final manuscript.Acknowledgements
The previous construction of the DGFS was supported by a grant from the
French National Agency of Research (ANR-11-JSV1-0008-01). The present
PREDICT-DGF study is supported by a grant from the French Ministry of
Health (PHRC-13-0523, 2013) and by a subvention from Sanofi. The protocol
was also independently peer reviewed by this institution.
Author details
1ITUN and Inserm U1064, Nantes University, 30 Boulevard Jean Monnet,
Nantes 44035, France. 2SPHERE (EA4275), Nantes University, Nantes, France.
3Délégation à la recherche clinique et à l’innovation, CHU Nantes, Nantes,
France. 4Néphrologie, Transplantation et Immunologie Clinique, Hôpital
Edouard Herriot, Lyon, France. 5Service de Néphrologie, Dialyse et
Transplantation, Hôpital Lapeyronie and Université Montpellier I, Montpellier,
France. 6Service de Néphrologie, Hôpital Pasteur, Nice, France. 7Service de
Transplantation Rénale, CHU Brabois, Nancy, France. 8Service de
Transplantation Rénale et de Soins Intensifs, Hôpital Necker, APHP and
Universités Paris Descartes et Sorbonne Paris Cité, Paris, France. 9Centre
d’Investigation Clinique en Biothérapie, Nantes University Hospital, Nantes,
France. 10CENTAURE Fondation, Nantes, France.
Received: 28 November 2014 Accepted: 11 June 2015References
1. Giral-Classe M, Hourmant M, Cantarovich D, Dantal J, Blancho G, Daguin P,
et al. Delayed graft function of more than six days strongly decreases long-
term survival of transplanted kidneys. Kidney Int. 1998;54:972–8.
2. Remuzzi G, Lesti M, Gotti E, Ganeva M, Dimitrov BD, Ene-Iordache B, et al.
Mycophenolate mofetil versus azathioprine for prevention of acute rejection
in renal transplantation (MYSS): a randomised trial. Lancet. 2004;364:503–12.
3. Irish WD, Ilsley JN, Schnitzler MA, Feng S, Brennan DC. A risk prediction
model for delayed graft function in the current era of deceased donor renal
transplantation. Am J Transpl. 2010;10:2279–86.
4. Jeldres C, Cardinal H, Duclos A, Shariat SF, Suardi N, Capitanio U, et al.
Prediction of delayed graft function after renal transplantation. Can Urol
Assoc J. 2009;3:377–82.
5. Chapal M, Le Borgne F, Legendre C, Kreis H, Mourad G, Garrigue V, et al. A
useful scoring system for the prediction and management of delayed graft
function following kidney transplantation from cadaveric donors. Kidney Int.
2014;86:1130–9.
6. Kaden J, May G, Strobelt V, Groth J, Muller P. Intraoperative T-cell depletion
prior to completion of anastomoses by high-dose single ATG bolus as a
new approach to improve long-term results after kidney transplantation.
Transpl Proc. 1997;29:344–7.
7. Kyllonen LE, Eklund BH, Pesonen EJ, Salmela KT. Single bolus antithymocyte
globulin versus basiliximab induction in kidney transplantation with
cyclosporine triple immunosuppression: efficacy and safety. Transplantation.
2007;84:75–82.
8. Turunen AJ, Lindgren L, Salmela KT, Kyllonen LE, Makisalo H, Siitonen SM,
et al. Association of graft neutrophil sequestration with delayed graft
function in clinical renal transplantation. Transplantation. 2004;77:1821–6.
9. Haririan A, Morawski K, Sillix DH, El-Amm JM, Garnick J, West MS, et al.
Induction therapy with basiliximab versus Thymoglobulin in African-
American kidney transplant recipients. Transplantation. 2005;79:716–21.
10. Mourad G, Rostaing L, Legendre C, Garrigue V, Thervet E, Durand D.
Sequential protocols using basiliximab versus antithymocyte globulins in
renal-transplant patients receiving mycophenolate mofetil and steroids.
Transplantation. 2004;78:584–90.
11. Sollinger H, Kaplan B, Pescovitz MD, Philosophe B, Roza A, Brayman K, et al.
Basiliximab versus antithymocyte globulin for prevention of acute renal
allograft rejection. Transplantation. 2001;72:1915–9.
Chapal et al. Trials  (2015) 16:282 Page 6 of 612. Ulrich F, Niedzwiecki S, Pascher A, Kohler S, Weiss S, Fikatas P, et al.
Long-term outcome of ATG vs. Basiliximab induction. Eur J Clin Invest.
2011;41:971–8.
13. Noel C, Abramowicz D, Durand D, Mourad G, Lang P, Kessler M, et al.
Daclizumab versus antithymocyte globulin in high-immunological-risk renal
transplant recipients. J Am Soc Nephrol. 2009;20:1385–92.
14. Preville X, Flacher M, LeMauff B, Beauchard S, Davelu P, Tiollier J, et al.
Mechanisms involved in antithymocyte globulin immunosuppressive
activity in a nonhuman primate model. Transplantation. 2001;71:460–8.
15. Chappell D, Beiras-Fernandez A, Hammer C, Thein E. In vivo visualization of
the effect of polyclonal antithymocyte globulins on the microcirculation after
ischemia/reperfusion in a primate model. Transplantation. 2006;81:552–8.
16. Aiello S, Cassis P, Mister M, Solini S, Rocchetta F, Abbate M, et al. Rabbit
anti-rat thymocyte immunoglobulin preserves renal function during
ischemia/reperfusion injury in rat kidney transplantation. Transpl Int.
2011;24:829–38.
17. Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D. Rabbit
antithymocyte globulin versus basiliximab in renal transplantation. N Engl J
Med. 2006;355:1967–77.
18. Levey A, Coresh J, Greene T, STevens L, Zhang Y, Hendriksen S, et al. Using
standardized serum creatinine values in the modification of diet in renal
disease study equation for estimating glomerular filtration rate. Ann Intern
Med. 2006;145:247–54.
19. Meas-Yedid V, Servais A, Noel LH, Panterne C, Landais P, Herve N, et al. New
computerized color image analysis for the quantification of interstitial
fibrosis in renal transplantation. Transplantation. 2011;92:890–9.
20. Walker AM. Low Power and Striking Results — A Surprise but Not a
Paradox. N Engl J Med. 1995;332:1091–2.
21. Knottnerus JA, Bouter LM. The ethics of sample size: two-sided testing and
one-sided thinking. J Clin Epidemiol. 2001;54:109–10.
22. R Core Team. R: A Language and environment for statistical computing. R
Foundation for Statistical Computing Vienna, Austria; 2010. 3-900051-07-0.
http://www.R-project.org/.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
